HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Nakaraang pagsara
$4.47
Sakop ng araw
$4.38 - $4.65
Sakop ng taon
$2.71 - $5.10
Market cap
864.56M USD
Average na Volume
1.34M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 10.74M | 522.19% |
Gastos sa pagpapatakbo | 8.45M | -61.55% |
Net na kita | 2.52M | 112.74% |
Net profit margin | 23.49 | 102.05% |
Kita sa bawat share | 0.01 | 109.05% |
EBITDA | 1.92M | 109.15% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 98.09M | -30.92% |
Kabuuang asset | 103.27M | -35.48% |
Kabuuang sagutin | 20.29M | -46.02% |
Kabuuang equity | 82.98M | — |
Natitirang share | 191.70M | — |
Presyo para makapag-book | 10.40 | — |
Return on assets | 4.34% | — |
Return on capital | 5.54% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 2.52M | 112.74% |
Cash mula sa mga operasyon | -15.75M | -8.58% |
Cash mula sa pag-invest | 15.61M | 58.83% |
Cash mula sa financing | 453.00K | -98.14% |
Net change in cash | 336.00K | -98.29% |
Malayang cash flow | -13.34M | -87.90% |
Tungkol
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Itinatag
2007
Headquarters
Website
Mga Empleyado
44
